STRO logo

Sutro Biopharma (STRO) Company Overview

Profile

Full Name:

Sutro Biopharma, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

September 27, 2018

Indexes:

Not included

Description:

Sutro Biopharma, known as STRO, is a biotechnology company focused on developing innovative cancer treatments. They use a unique technology to create targeted therapies that aim to improve patient outcomes. Their goal is to provide effective and personalized medicines for patients with various types of cancer.

Key Details

Price

$2.15

Annual Revenue

$153.73 M(+126.84% YoY)

Annual EPS

-$1.78(+24.26% YoY)

Annual ROE

-58.25%

Beta

2.15

Events Calendar

Earnings

Next earnings date:

Mar 25, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 25, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 11, 24 Wells Fargo
Equal-Weight
Dec 11, 24 JMP Securities
Market Outperform
Nov 18, 24 HC Wainwright & Co.
Buy
Oct 11, 24 Piper Sandler
Overweight
Oct 11, 24 HC Wainwright & Co.
Buy
Sep 16, 24 JMP Securities
Market Outperform
Sep 16, 24 HC Wainwright & Co.
Buy
Aug 16, 24 Truist Securities
Buy
Aug 14, 24 HC Wainwright & Co.
Buy
May 15, 24 Oppenheimer
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
STRO
seekingalpha.comJanuary 2, 2025

STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promising efficacy in ovarian cancer, with manageable toxicity, positioning it for potential Accelerated Approval by mid-2027. Financially, STRO has a two-year runway with current cash reserves, but further financing may be needed, risking shareholder dilution.

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
STRO
zacks.comNovember 18, 2024

Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
STRO
zacks.comNovember 13, 2024

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago.

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
STRO
globenewswire.comNovember 13, 2024

- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
STRO
seekingalpha.comSeptember 23, 2024

STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments.

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
STRO
globenewswire.comSeptember 14, 2024

- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) -

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
STRO
zacks.comAugust 13, 2024

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.64 per share a year ago.

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
globenewswire.comAugust 13, 2024

- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 -

Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
STRO
Zacks Investment ResearchMay 13, 2024

Sutro Biopharma (STRO) lacks the necessary elements for a potential earnings surprise in its upcoming report. Be ready with the key projections.

Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
STRO
Zacks Investment ResearchMarch 25, 2024

Sutro Biopharma, Inc. (STRO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.82 per share. This compares to loss of $0.61 per share a year ago.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Sutro Biopharma?
  • Does Sutro Biopharma pay dividends?
  • What sector is Sutro Biopharma in?
  • What industry is Sutro Biopharma in?
  • What country is Sutro Biopharma based in?
  • When did Sutro Biopharma go public?
  • Is Sutro Biopharma in the S&P 500?
  • Is Sutro Biopharma in the NASDAQ 100?
  • Is Sutro Biopharma in the Dow Jones?
  • When was Sutro Biopharma's last earnings report?
  • When does Sutro Biopharma report earnings?
  • Should I buy Sutro Biopharma stock now?

What is the ticker symbol for Sutro Biopharma?

The ticker symbol for Sutro Biopharma is NASDAQ:STRO

Does Sutro Biopharma pay dividends?

No, Sutro Biopharma does not pay dividends

What sector is Sutro Biopharma in?

Sutro Biopharma is in the Healthcare sector

What industry is Sutro Biopharma in?

Sutro Biopharma is in the Biotechnology industry

What country is Sutro Biopharma based in?

Sutro Biopharma is headquartered in United States

When did Sutro Biopharma go public?

Sutro Biopharma's initial public offering (IPO) was on September 27, 2018

Is Sutro Biopharma in the S&P 500?

No, Sutro Biopharma is not included in the S&P 500 index

Is Sutro Biopharma in the NASDAQ 100?

No, Sutro Biopharma is not included in the NASDAQ 100 index

Is Sutro Biopharma in the Dow Jones?

No, Sutro Biopharma is not included in the Dow Jones index

When was Sutro Biopharma's last earnings report?

Sutro Biopharma's most recent earnings report was on Nov 13, 2024

When does Sutro Biopharma report earnings?

The next expected earnings date for Sutro Biopharma is Mar 25, 2025

Should I buy Sutro Biopharma stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions